Claims
- 1. Therapeutic or prophylactic composition comprising fibronectin-binding protein I (SfbI) as an immunological adjuvant for any antigen or immunogen.
- 2. Composition of claim 1 wherein said SfbI lacks at least one of its anchor domain and signal domain.
- 3. Composition of claim 1 comprising at least one portion of SfbI.
- 4. Composition of claim 1 comprising an antigen in addition to SfbI.
- 5. Composition of claim 4 comprising a soluble antigen.
- 6. Composition of claim 4 wherein the antigen and SfbI have been obtained by co-expression.
- 7. Composition of claim 6 wherein expression is carried out by means of a carrier strain.
- 8. Composition of claim 7 wherein expression is carried out by news of a vaccine carrier strain.
- 9. Composition of claim 4 wherein the antigen and the SfbI are coupled to each other.
- 10. Composition of claim 4 wherein the antigen and SfbI form a fusion protein (chimeric protein).
- 11. Composition of claim 10 wherein the antigen and SfbI form an expression product.
- 12. Composition of claim 10 wherein expression is carried out by means of a carrier strain.
- 13. Composition of claim 12 wherein expression is carried out by means of a vaccine carrier strain.
- 14. Composition of claim 1 wherein the antigen and SfbI have been expressed by different carrier strains.
- 15. Composition of claim 2 wherein the antigen and SfbI have been expressed by different carrier strains.
- 16. Composition of claim 3 wherein the antigen and SfbI have been expressed by different carrier strains.
- 17. Composition of claim 4 wherein the antigen and SfbI have been expressed by different carrier strains.
- 18. Composition of claim 5 wherein the antigen and SfbI have been expressed by different carrier strains.
- 19. Composition of claim 6 wherein the antigen and SfbI have been expressed by different carrier strains.
- 20. Composition of claim 7 wherein the antigen and SfbI have been expressed by different carrier strains.
- 21. Composition of claim 1 adapted for a administration by a mucosal route.
- 22. Composition of claim 15 adapted for administration by an intranasal route.
Priority Claims (2)
Number |
Date |
Country |
Kind |
97 108 403.3 |
May 1997 |
EP |
|
97 120 941.6 |
Nov 1997 |
EP |
|
CROSS-REFERENCE TO RELATE APPLICATION
[0001] This is a continuation of International Application No. PCT/EP98/03056 filed May 22, 1998, the entire disclosure of which is incorporated by reference.
Continuations (2)
|
Number |
Date |
Country |
Parent |
09441239 |
Nov 1999 |
US |
Child |
10059670 |
Jan 2002 |
US |
Parent |
PCT/EP98/03056 |
May 1998 |
US |
Child |
09441239 |
Nov 1999 |
US |